Agenda

All times displayed for Europe/Berlin timezone.

M&A Forum

Where do mega-mergers leave smaller players, what will be the role of the entrepreneurs driving innovation, and what are the more practical implications for companies going through the expensive and disruptive merger process?
15:30 - 17:30 Entrente Room, Hall 4
M&A Forum

2019 kicked off with USD$91.23 billion* worth of high-profile acquisitions in the United States alone, including Bristol Myers Squibb’s purchase of Celgene, and Eli Lilly’s takeover of Loxo Oncology. An impressive start to the year, but will this continue at pace throughout 2019 and what’s the outlook for 2020? AS Pharma companies turn more to acquisitions to acquire new technologies, boost pipelines and increase capability, we ask what the fallout of a shrinking market may be. Where do mega-mergers leave smaller players, what will be the role of the entrepreneurs driving innovation, and what are the more practical implications for companies going through the expensive and disruptive merger process?

This roundtable will address the current M&A landscape, analyse deal drivers in-depth, and examine the potential implications of so much consolidation. This free to attend event will give you the opportunity to hear from dealmakers, investors and innovators on the current outlook, and will provide an important opportunity for networking at CPhI Worldwide.

*Source: GlobalData

It's free to attend, but seats are limited – please register your interest HERE!

Presentation: Deals, Deal Deals: Analysis of 2019 and Outlook for 2020
15:30 - 16:00 Entrente Room, Hall 4
M&A Forum

Speaker: Representative, Informa Market Intelligence

It's free to attend, but seats are limited – please register your interest HERE!

Panel discussion: Assessing the M&A Landscape for Pharma
16:00 - 17:00 Entrente Room, Hall 4
M&A Forum
Chief Corporate Development Officer
Advanz Pharma
Executive Partner & Founder
GHO Capital
Executive Vice President Corporate Development
Recipharm AB

•Key factors driving deal activity, will this continue at pace?
•Assessing the targets: chronic disease, HPAPI, cell and gene therapies, biologics
•A changing market: what are the implications of vertical integration and consolidation, where does this leave SMEs?
•Impact on innovation & R&D, what’s the role of the entrepreneur amidst so much consolidation?
•Internal dynamics: What’s the fallout of M&A on staff and senior leadership?

It's free to attend, but seats are limited – please register your interest HERE!

Refreshments & Networking
17:00 - 17:30 Entrente Room, Hall 4
M&A Forum